Bayer

News

The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.

News

FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.

News

Armed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis.

News

Bayer has agreed terms for its first biopharma takeover in years, paying $300m upfront for Perfuse and its novel drug implant for eye diseases.

News

Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that combines in silico and wet-lab work in a single application.

News

Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.